Not medical advice. Talk to your provider before using any peptide. Full disclaimer
Liraglutide
Beginner tier: 600 mcg, daily · FDA label
Also known as: Victoza, Saxenda, NN2211
Over 9,300 patients in the LEADER trial. A 13% drop in major cardiovascular events. Liraglutide (Victoza, Saxenda) is a GLP-1 receptor agonist with two FDA approvals and more than 15 years of real-world safety data. The SCALE trial landed on 8% mean weight loss at 56 weeks with the 3 mg dose. That's less than semaglutide, and honesty about that matters. Liraglutide's 13-hour half-life means side effects wash out in about a day if you stop. That short clearance time is why many clinicians still reach for it first, especially for patients new to GLP-1 therapy or those with a history of GI sensitivity.
What Is Liraglutide?
A 13% reduction in heart attacks, strokes, and cardiovascular death across 9,340 patients over 3.8 years. That LEADER trial finding [1] made liraglutide the first GLP-1 drug proven to protect the heart. Liraglutide (also sold as Victoza for diabetes and Saxenda for weight management) is a modified version of human GLP-1 with 97% amino acid homology to the native hormone. A palmitic acid chain at position 26 lets it bind albumin in the blood. That binding shields it from DPP-IV breakdown and extends the half-life from about 2 minutes to roughly 13 hours, long enough for once-daily dosing.
On the weight side, the SCALE Obesity and Prediabetes trial (n=3,731)[2] showed 8.0% mean body weight loss at 56 weeks on the 3 mg dose versus 2.6% on placebo. A head-to-head comparison in STEP 8 (PMC8753508) put those numbers in context: semaglutide 2.4 mg weekly produced 15.8% loss versus 6.4% for liraglutide 3 mg daily over 68 weeks.
The practical picture for most users looks like this: a pre-filled pen (no mixing needed), weekly dose increases from 0.6 mg up to 3.0 mg, and GI side effects that peak during titration but usually settle within a few weeks. Appetite suppression kicks in within days of the first injection. FDA approved Teva's generic of Saxenda in August 2025.
How Liraglutide Works
A C-16 fatty acid (palmitic acid) attached via a glutamic acid spacer at position 26. That single modification gives liraglutide its clinical utility. The palmitic acid promotes non-covalent binding to serum albumin, which does two things: it shields the molecule from DPP-IV and neutral endopeptidase degradation, and it slows absorption from the subcutaneous injection site. Native GLP-1 has a plasma half-life of about 2 minutes. Liraglutide's is roughly 13 hours.
Once circulating, liraglutide activates GLP-1 receptors across multiple tissues. In the pancreas, it boosts glucose-dependent insulin secretion and suppresses inappropriate glucagon release. The glucose-dependent part is important; hypoglycemia risk stays low when liraglutide is used alone because insulin release only ramps up when blood sugar is raised.
In the GI tract, gastric emptying slows by 10 to 15%. In the brain, liraglutide acts on hypothalamic and brainstem GLP-1 receptors to reduce appetite and food reward signaling. The cardiovascular protection spotted in LEADER [1] likely involves direct effects on vascular endothelial function and anti-inflammatory pathways, though the exact mechanisms are still being mapped out.
Liraglutide Benefits
- Liraglutide benefits center on proven weight loss, cardiovascular protection, and a safety profile backed by more than a decade of post-market data.
- 8.0% mean body weight loss at 56 weeks on 3 mg daily in the SCALE trial (n=3,731)[2]. Real-world results typically land between 5% and 8%.
- Cardiovascular protection confirmed in LEADER (n=9,340): 13% reduction in major adverse cardiovascular events over 3.8 years of follow-up [1]. That trial was one of the first to prove a diabetes drug could protect the heart.
- Short half-life (13 hours) means side effects clear within about a day if you need to pause. Semaglutide's weekly dosing locks you in for seven days if problems arise.
- No reconstitution or mixing. Saxenda ships as a pre-filled pen. Dial your dose and inject.
- Approved for adolescent obesity (ages 12 and up) since 2020, making it one of the few GLP-1 options with a pediatric indication.
- HbA1c reductions of 1.1% to 1.4% at the Victoza dose range (1.2 to 1.8 mg daily), with blood sugar improvements reported even in non-diabetic users.
Liraglutide: Science vs Community Consensus
FDA-approved for chronic weight management (Saxenda, 3 mg/day) and type 2 diabetes (Victoza, up to 1.8 mg/day).
Read the evidence (key study, limitations)
Strong RCT evidence for ~8% weight loss at 56 weeks and 13% MACE reduction in high-CV-risk T2D. Well-characterized safety profile after 15+ years on market. Less effective than semaglutide or tirzepatide for weight loss.
SCALE Obesity and Prediabetes (PMID 26132939): n=3,731, 3 mg/day vs placebo, 56 wk: 8.0% vs 2.6% mean weight loss. LEADER (PMID 27295427): n=9,340 T2D high-CV-risk, 3.8-yr median follow-up: 13% MACE reduction (HR 0.87, 95% CI 0.78-0.97). STEP 8 head-to-head (PMC8753508): semaglutide 2.4 mg/wk vs liraglutide 3 mg/day, 68 wk: −15.8% vs −6.4% weight loss.
Substantially less effective than semaglutide (-6.4% vs -15.8% in STEP 8) and tirzepatide. Daily injection vs once-weekly alternatives. Weight regain expected on discontinuation. Black box warning for medullary thyroid carcinoma (rodent data only; LEADER found 0 MTC in liraglutide arm vs 1 placebo). Slight numerical imbalance in total malignancies in LEADER (10.1% liraglutide vs 9.0% placebo, HR ~1.06, not statistically significant: clinical relevance unclear). Pancreatitis rate similar to placebo in LEADER.
Regarded as the "old reliable" GLP-1: effective, well-understood, and now accessible via generic and compounding.
Read the reports (what users report 6, common issues 7)
Most users follow the FDA titration closely. The daily injection and lower weight loss vs semaglutide drive switching; many transition to semaglutide or tirzepatide after experiencing or researching the options.
- Appetite suppression begins within days of first dose
- Nausea clears faster than with semaglutide: drug washes out in ~1 day if you need to pause
- Daily short half-life allows dose flexibility and faster side-effect recovery
- Now cheaper via the Teva generic and compounded 503A versions
- Consistent 1–2 lb/week loss once at therapeutic dose
- Improves fasting glucose and insulin sensitivity: reported even in non-diabetics
- Nausea is prevalent during titration: ~40% at 3 mg dose
- Daily injection burden vs once-weekly alternatives
- Many switch to semaglutide for better weight loss after stalling
- Hair thinning reported (telogen effluvium from rapid weight loss, not direct drug effect)
- Constipation common at maintenance dose
- GI side effects can limit ability to reach the 3 mg dose
- Cost: brand-name Saxenda is expensive without insurance
Community closely follows FDA titration protocol. Real-world outcomes (~5–8% weight loss at maintenance) are consistent with trial data. The primary divergence is that many community users elect to stay at sub-maximal doses (1.2–1.8 mg) rather than pushing to 3.0 mg: driven by tolerability, not ignorance of dosing. No significant off-label dose escalation patterns observed.
Liraglutide Dosage Guide
| Level | Dose / Injection | Frequency |
|---|---|---|
| Beginner | 600 mcg | Daily |
| Moderate | 1.8 mg | Daily |
| Aggressive | 3 mg | Daily |
Liraglutide comes as a pre-filled pen, so there's no reconstitution math to worry about. Saxenda pens hold 18 mg total and deliver doses from 0.6 mg to 3.0 mg via a dial selector. At the 3 mg maintenance dose, one pen lasts 6 days.
For compounded liraglutide from 503A pharmacies, the common concentration is 6 mg/mL. With that concentration in a standard insulin syringe: 10 units equals 0.6 mg, 20 units equals 1.2 mg, 30 units equals 1.8 mg, 40 units equals 2.4 mg, and 50 units equals 3.0 mg.
The thing most beginners miss: if you skip more than 3 consecutive days, you need to restart at 0.6 mg and re-titrate. Jumping back to your prior dose after a gap causes disproportionate GI distress. Keep your pens on schedule or plan for the ramp back up. Store unused pens in the fridge (2 to 8 degrees Celsius). Once you start using a pen, it can stay at room temperature (up to 30 degrees Celsius) for 30 days.
Cycling
No scheduled off period.
Designed for continuous long-term use. Weight regain expected after discontinuation. If you miss more than 3 consecutive days, restart at 0.6mg and re-titrate.
Liraglutide is an FDA-approved chronic weight management medication designed for continuous long-term use. Cycling is not recommended: discontinuation results in weight regain. Users who stop liraglutide and wish to restart after a gap of >3 days should re-titrate from 0.6 mg to minimize GI side effects.
- If stopping due to adverse effects: slow taper (step down one dose level per week) to minimize rebound hunger
- Weight regain begins within weeks of discontinuation: plan for ongoing therapy or transition to another GLP-1
- If stopping for surgery: follow anesthesiologist guidance on GLP-1 washout (typically 1 week minimum due to gastric emptying effects)
Or use the universal Peptide Calculator for any peptide.
Liraglutide Protocols by Goal
Expected: ~8% mean body weight loss at 56 weeks (SCALE trial); real-world 5–8% typical
Monitor: Check fasting glucose, HbA1c, lipid panel, and gallbladder symptoms at baseline and 3–6 months. Monitor body weight at each visit. Screen for pancreatitis symptoms (severe abdominal pain radiating to back: stop immediately).
How to Inject Liraglutide
- 1Step 1
Remove the pen from the refrigerator 15 to 30 minutes before injecting. Room-temperature solution reduces injection discomfort.
- 2Inspect the solution
It should be clear and colorless. Do not use if cloudy or if you see particles.
- 3Attach a new pen needle (32-gauge is standard for Saxenda)
Remove both the outer and inner needle caps.
- 4Step 4
If using the pen for the first time or if it's been stored without a needle, prime by dialing to 0.6 mg and pressing the dose button until solution appears at the needle tip.
- 5Dial your prescribed dose
Titration schedule for Saxenda: 0.6 mg daily for week 1, 1.2 mg for week 2, 1.8 mg for week 3, 2.4 mg for week 4, then 3.0 mg ongoing.
- 6Step 6
Choose your injection site: abdomen or upper arm for best absorption. The thigh works but absorption drops by about 22%. Rotate sites; avoid the same spot for at least a week.
- 7Step 7
Pinch the skin, insert the needle at 90 degrees, press the dose button, and hold for 6 seconds before withdrawing.
- 8Remove and safely dispose of the needle after each use
Replace the pen cap. Never store the pen with a needle attached.
For compounded liraglutide (6 mg/mL concentration): draw 10 units on a standard insulin syringe for 0.6 mg, 20 units for 1.2 mg, 30 units for 1.8 mg, 40 units for 2.4 mg, or 50 units for 3.0 mg. Inject subcutaneously at the same sites. 29 to 31 gauge, half-inch needle.
Timing is flexible. Inject at the same time each day, with or without meals.
Liraglutide Stacking Protocols
Works With
Community-reported fat-loss pairing: AOD-9604 targets adipose lipolysis via a different mechanism (GH fragment). No clinical interaction data; anecdotal stacking for additional fat mobilization.
Used by community to manage GLP-1-induced GI side effects. BPC-157 is a gut mucosal healing peptide; anecdotally reported to reduce liraglutide-related nausea and GI discomfort. No clinical trial data for this combination.
Amylin analog clinically studied in combination with semaglutide (CagriSema) for additive weight loss. With liraglutide, a combined effect is theoretical: complementary mechanism via amylin receptor. No liraglutide-specific combo trial.
Research-stage only; no established human dosing for liraglutide + cagrilintide combination
Avoid
Using liraglutide with insulin may raise the risk of hypoglycemia, including severe hypoglycemia. The Victoza label says to consider a lower insulin dose when starting liraglutide (section 7.2). Saxenda says a lower insulin dose may reduce the risk and adds blood glucose checks in type 2 diabetes (section 5.4).
Using liraglutide with a sulfonylurea may raise the risk of hypoglycemia, including severe hypoglycemia. The Victoza label says to consider a lower sulfonylurea dose when starting liraglutide (section 7.2). Saxenda says a lower dose may reduce the risk (section 5.4).
Liraglutide reduces digoxin AUC by ~16% and Cmax by ~31% via delayed gastric emptying. Monitor digoxin levels if co-administering.
Estimated Cost
Pricing updated 2026-04-09
Liraglutide Side Effects
Liraglutide carries a black box warning for medullary thyroid carcinoma. In rodent studies, liraglutide caused dose-dependent thyroid C-cell tumors at exposures 8 times the human dose. No confirmed human cases appeared in the LEADER trial (0 MTC in the liraglutide arm versus 1 in placebo, n=9,340). Still, the warning makes liraglutide off-limits for anyone with a personal or family history of MTC or Multiple Endocrine Neoplasia syndrome type 2 (MEN2).
GI side effects are the most common reason people quit. Nausea hits roughly 40% of users at the 3 mg dose. Vomiting, diarrhea, and constipation affect 15 to 20%. The pattern is predictable: symptoms peak during each dose increase and fade over 2 to 3 weeks at a stable dose. Slow titration (advancing by 0.6 mg per week as labeled) reduces the severity. Some community users extend to 2 weeks per step if nausea is severe.
Pancreatitis occurs in under 0.4% of patients. The LEADER trial found rates similar to placebo, but the risk is real. Severe abdominal pain radiating to the back, with or without vomiting, means stop the drug and get evaluated immediately.
Gallbladder disease showed up in about 2.2% of SCALE trial participants. GLP-1 receptor agonists slow gallbladder emptying, and rapid weight loss adds to gallstone risk. Right upper quadrant pain warrants an ultrasound.
LEADER turned up a slight numerical imbalance in total malignancies (10.1% liraglutide versus 9.0% placebo, HR approximately 1.06). This was not statistically significant. The clinical meaning is unclear, but it was observed and should be noted.
Hypoglycemia is rare when liraglutide is used alone. It becomes a genuine risk when combined with insulin or sulfonylureas; dose reductions of those medications are often needed. Injection site reactions are mild and infrequent.
Hair thinning (telogen effluvium) shows up in community reports. This is driven by rapid weight loss rather than a direct drug effect. It's typically self-limiting.
When to seek medical attention: severe abdominal pain, persistent vomiting, signs of allergic reaction, or any visual changes. Stop liraglutide at least 2 months before planned conception; the drug was detected in milk of lactating rats, and human data on infant risk are insufficient.
Common Issues & Solutions
Nausea peaks at each dose increase: if severe, hold current dose for 2 extra weeks before advancing rather than stopping. Ginger tea, small bland meals, and morning dosing (after breakfast) help most users.
If you miss more than 3 consecutive days, restart titration at 0.6 mg: jumping back to your prior dose after a gap causes disproportionate GI side effects.
Constipation at maintenance dose (3 mg) is common: increase fluid intake to ≥2.5L/day, add 25–35 g dietary fiber, consider osmotic laxative (MiraLax) if persistent.
Injection site lumps or reactions: rotate sites each injection: abdomen, thigh, upper arm. Avoid the same spot for at least 1 week. Brand Saxenda pen is a large 32-gauge needle; room-temperature pen reduces injection discomfort.
Weight plateau after initial loss: confirm you are at the 3.0 mg dose. If already at 3 mg and plateaued, review caloric intake: liraglutide suppresses appetite but does not override a significant caloric surplus. Consider switching to semaglutide or tirzepatide for additional efficacy.
Ask AI about this page
Ask AI for a second opinion on Liraglutide dosing and side effects
Contraindications
- Personal or family history of medullary thyroid carcinoma (MTC)
- Multiple Endocrine Neoplasia syndrome type 2 (MEN2)
- History of pancreatitis
- Pregnancy or planning to become pregnant (stop at least 2 months before conception)
- Breastfeeding: liraglutide was detected in milk of lactating rats; human data are insufficient to assess infant risk
- Known hypersensitivity to liraglutide
- Severe renal impairment (eGFR <15 mL/min): limited data, use with caution per FDA label Section 8.6
Drug Interactions
- Insulin and sulfonylureas: increased hypoglycemia risk, dose reduction often needed
- Oral medications may have delayed absorption due to slowed gastric emptying
- Digoxin: AUC reduced by approximately 16%; monitor levels
- Oral contraceptives: Cmax fell 12% for ethinyl estradiol and 13% for levonorgestrel, and Tmax came 1.5 hours later. AUC did not drop (Saxenda and Victoza labels, section 12.3)
- Oral contraceptives and oral hormonal therapies: the Saxenda and Victoza labels call for no backup contraception and set no dose timing. Both advise caution with oral drugs, since liraglutide slows gastric emptying (section 7.1)
Product Quality
Brand-name Saxenda and Victoza are FDA-approved pre-filled pens with Novo Nordisk manufacturing quality controls: quality risk is minimal. Teva generic (launched August 2025) is FDA-approved and bioequivalent. Compounded liraglutide from 503A pharmacies (PCAB-accredited, COA-verified) represents low-to-medium risk: liraglutide remains on FDA's shortage list, but quality depends entirely on the specific pharmacy.
- Brand or Teva generic pens dispensed by licensed US pharmacies carry minimal counterfeiting risk
- Compounded liraglutide: a Certificate of Analysis (COA) for each batch confirms potency and purity
- Verify compounding pharmacy is PCAB-accredited or 503A-licensed in your state
- Store unused pens refrigerated (2–8°C); in-use pen can be at room temp (≤30°C) up to 30 days
- Discard pen if solution is not clear and colorless: do not use if particulate matter or cloudiness present
Recommended Monitoring
| Test | When | Target |
|---|---|---|
| Body weight | Baseline, then monthly | Not listed |
| Fasting glucose and HbA1c | Baseline, then every 3 months | HbA1c <7.0% (T2D), fasting glucose 70–100 mg/dL |
| Lipid panel | Baseline, then every 6 months | Not listed |
| Liver function tests (AST, ALT) | Baseline, then every 6 months | Not listed |
| Amylase / Lipase | If symptoms of pancreatitis develop (severe abdominal pain radiating to back, nausea/vomiting) | Not listed |
| Gallbladder ultrasound | If right upper quadrant pain or cholecystitis symptoms develop | Not listed |
| Heart rate | Each clinical visit | Not listed |
| Serum calcitonin | Baseline and annually if monitoring thyroid cancer risk (family history of MTC or MEN2: though liraglutide is contraindicated in these patients) | Not listed |
Primary efficacy measure; if <4% weight loss at 16 weeks on 3 mg, reassess therapy
For T2D patients or those with prediabetes. Liraglutide improves glycemic control even in non-diabetics
Weight loss and GLP-1 action improve triglycerides and LDL; monitor for gallbladder-related lipid changes
Not required by FDA label but prudent for long-term users given metabolic changes and fatty liver context
Pancreatitis risk exists with GLP-1 class; rate similar to placebo in LEADER but monitor for symptoms
Gallbladder disease incidence 2.2% in SCALE trial; GLP-1s slow gallbladder emptying
GLP-1 RAs modestly increase resting heart rate; relevant for patients with pre-existing arrhythmia or cardiac history
Black box warning for medullary thyroid carcinoma based on rodent data; no confirmed human cases in LEADER
Liraglutide Before and After
Titration phase: dose increases weekly from 0.6mg to 2.4mg. Appetite suppression begins within days. Nausea most common but typically improves.
Full dose (3mg) reached. Noticeable reduction in hunger. Most see 2-4% body weight loss by week 8.
Steady weight loss of 0.5-1 lb per week. Blood sugar improvements measurable on labs.
Weight loss approaches 8% average from SCALE trial. Cardiovascular markers improve. Rate slows near equilibrium.
What to Expect
Weeks 1 through 4, Titration. The dose advances weekly from 0.6 mg to 2.4 mg. Appetite suppression is measurable by week 2 in most users. GI side effects peak during each dose step; nausea is the most common complaint and hits roughly 40% at therapeutic doses. Community reports consistently describe noticeably reduced appetite within 3 to 5 days of the first injection. Most people see 1 to 3 pounds of loss in the first month, driven by reduced caloric intake rather than any direct metabolic effect.
Weeks 5 through 8, Full Dose. At 3.0 mg daily, GLP-1 receptor engagement reaches its maximum. SCALE trial data predicts 2 to 4% body weight loss by week 8. Users describe the reduction in "food noise" as the most noticeable change. Smaller portions feel satisfying. GI side effects typically start improving from their peak. Community reports land on 2 to 5 pounds of additional loss in this window. Constipation and fatigue are common but usually resolve. Mild nausea continues to diminish.
Weeks 9 through 26, Active Loss Phase. Steady progressive weight loss averages 0.5 to 1 pound per week. Blood glucose improvements become measurable on lab work. SCALE data shows approximately 6% weight loss by week 26. Some users hit plateaus at the 1 to 2 month mark; these typically resolve with caloric adjustment or dose confirmation. Hair thinning (telogen effluvium from the weight loss itself, not a direct drug effect) may appear during this window. It is typically self-limiting.
Weeks 27 through 56, Deceleration. The SCALE trial's primary endpoint sits here: 8.0% mean weight loss at 56 weeks. The rate of loss slows as the body adjusts to a new equilibrium. Cardiovascular markers, blood pressure, and lipid profiles continue to improve. Many community users transition to semaglutide or tirzepatide during this window if they want additional loss. Those who stay on liraglutide report satisfaction with maintained weight and improved metabolic markers. Cost becomes the primary concern at this stage. Gallstone risk increases with prolonged weight loss; cholecystitis occurred in roughly 2.2% of SCALE participants.
Detailed Timeline: Science vs Community
Dose advances weekly: 0.6 → 1.2 → 1.8 → 2.4 mg. Appetite suppression measurable by week 2. GI side effects peak during dose steps.
Nausea most common complaint. Appetite noticeably reduced within 3–5 days of first injection. Most see 1–3 lb loss in first month from reduced caloric intake.
At 3.0 mg, maximal GLP-1 receptor engagement. ~2–4% body weight loss expected by week 8 in SCALE trial data.
"Food noise" reduced. Smaller portions feel satisfying. GI side effects typically improving from peak. 2–5 lb loss reported in this window by most users.
Steady progressive weight loss at 0.5–1 lb/week average. Blood glucose improvements measurable. SCALE data shows ~6% weight loss by week 26.
Most users report consistent loss. Some plateau at 1–2 month marks: often resolve with caloric adjustment or dose confirmation. Hair thinning may appear (telogen effluvium from weight loss, typically self-limiting).
SCALE trial: 8.0% mean weight loss at 56 weeks. Rate slows as body adjusts. Cardiovascular markers, blood pressure, and lipid improvements continue.
Many users switch to semaglutide or tirzepatide in this window for additional loss. Those who stay report satisfaction with maintained weight and improved metabolic markers. Cost becomes the main issue at this stage.
Pharmacokinetics
Source: FDA Prescribing Information (Victoza), Section 12.3
Pharmacokinetics: Active Dose Over Time
t½ = ~13 hoursDisclaimer: This curve is a simplified first-order exponential decay model. Actual pharmacokinetics vary based on injection site, individual metabolism, body composition, and other factors. Half-life values are approximate and based on available preclinical and clinical literature. Many research peptides lack formal human pharmacokinetic studies. This is for educational purposes only, not medical advice.
Molecular Profile
Is Liraglutide Legal?
Liraglutide holds two active FDA approvals: Victoza (approved 2010) for type 2 diabetes at doses up to 1.8 mg daily, and Saxenda (approved 2014) for chronic weight management at 3.0 mg daily. Both are prescription-only medications.
FDA approved the first generic of Victoza (Hikma) in December 2024. Teva's generic of Saxenda followed in August 2025. FDA rates both as therapeutically equivalent to their brands. FDA approved two more Saxenda generics on February 24, 2026, from Biocon (ANDA 217063) and Orbicular (ANDA 217234). Drugs@FDA lists 11 approved liraglutide generics as of October 14, 2026: 8 rated equivalent to Victoza, 3 to Saxenda.
Compounded liraglutide is available from 503A pharmacies while liraglutide remains on the FDA drug shortage list. FDA's shortage data still listed it as current in October 2026. PCAB-accredited compounding pharmacies offer prescription access. A Certificate of Analysis (COA) documents potency and purity for each compounded batch.
Liraglutide does not appear on the World Anti-Doping Agency (WADA) 2026 Prohibited List. Among GLP-1 drugs, WADA's 2026 Monitoring Program names only semaglutide and tirzepatide. Athletes subject to anti-doping testing should verify current prohibited substance lists.
This content is for educational purposes only and does not constitute medical advice. Consult a licensed healthcare provider before starting any peptide therapy.
Who Should Consider Liraglutide
- Adults with BMI ≥30 (or ≥27 with weight-related comorbidity)
- Type 2 diabetics needing glycemic control with cardiovascular benefit
- Adolescents aged 12+ with obesity
- People who want a daily GLP-1 with faster side-effect clearance than weekly options
- Those new to GLP-1 therapy who prefer a conservative start
Related Peptides
What Changed for Liraglutide
- Safety
Corrected Oct 14, 2026: liraglutide with insulin or a sulfonylurea may call for a lower dose of that drug, not a do-not-combine, per the Victoza label.
What this does not mean: The risk is real: hypoglycemia, including severe hypoglycemia. Victoza says to consider a lower insulin or sulfonylurea dose when starting (section 7.2). Saxenda adds glucose checks in type 2 diabetes (section 5.4).
Source: Victoza (liraglutide) prescribing information (openFDA label record, SPL version 31, effective Oct 14, 2025; captured as the same-version DailyMed SPL XML) (opens in a new tab) · Saved copy
- Safety
Corrected Oct 13, 2026: liraglutide lowered pill hormone peaks 12 to 13% with no drop in AUC, and no backup contraception is advised, per the Saxenda label.
Before: Oral contraceptives: Cmax reduced by 12%, take at least 1 hour before injection; additional contraceptive precautions recommended during initiation and dose escalation (GLP-1 class wording) After: Cmax down 12% (ethinyl estradiol) and 13% (levonorgestrel), Tmax 1.5 hours later, AUC not lowered. The Saxenda and Victoza labels set no dose timing and call for no backup contraception
What this does not mean: The page had said to take the pill 1 hour before the injection; that timing comes from the Byetta and Adlyxin labels. The tirzepatide and orforglipron labels do call for backup contraception.
Source: Saxenda (liraglutide) prescribing information (openFDA label record, SPL version 22, effective Feb 25, 2026) (opens in a new tab) · Saved copy
- Regulatory
FDA extended comments on its 503B proposal for semaglutide, tirzepatide and liraglutide to Jul 30, 2026, per Federal Register 2026-12937.
What this does not mean: An extension of the comment period only. FDA has not made a final decision on the proposal.
Also covers: Semaglutide, Tirzepatide
Source: Federal Register 2026-12937 (91 FR 38719, Jun 26, 2026) (opens in a new tab) · Saved copy
- Regulatory
FDA proposed not to include semaglutide, tirzepatide and liraglutide on the 503B bulks list on May 1, 2026, per Federal Register 2026-08552.
What this does not mean: A proposal, not a final decision. It does not touch the FDA-approved brand products; it concerns bulk substances for outsourcing facilities.
Also covers: Semaglutide, Tirzepatide
Source: Federal Register 2026-08552 (91 FR 23431, May 1, 2026) (opens in a new tab) · Saved copy
- Safety
Saxenda labeling supplement S-025 took the suicidal behavior and ideation warning off the label on Feb 25, 2026, per the updated FDA label.
Source: Saxenda (liraglutide) prescribing information (openFDA label record, SPL version 22, effective Feb 25, 2026) (opens in a new tab) · Saved copy
- Safety
FDA asked makers to take the suicidal behavior and ideation warning off Saxenda, Wegovy and Zepbound labels on Jan 13, 2026, per an FDA safety communication.
What this does not mean: FDA found no increased risk of suicidal ideation or behavior in its review. The diabetes-only GLP-1 labels never carried this warning.
Also covers: Semaglutide, Tirzepatide
Source: FDA Drug Safety Communication, Jan 13, 2026: FDA requests removal of suicidal behavior and ideation warning from GLP-1 RA medications (opens in a new tab) · Saved copy
Peptide Schedule Research TeamReviewed Apr 7, 20269 Citations
References
- [1]LEADER Trial: Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes (opens in a new tab)PubMed (opens in a new tab)PubMed
- [2]A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management (Pi-Sunyer et al., N Engl J Med 2015) (opens in a new tab)(n=3,731,)PubMed (opens in a new tab)PubMed
Additional References
- Victoza (Liraglutide) FDA Prescribing Information (opens in a new tab)FDA Label
- Saxenda (Liraglutide 3.0 mg) FDA Prescribing Information (opens in a new tab)FDA Label
- Efficacy of Liraglutide for Weight Loss Among Patients With Type 2 Diabetes: The SCALE Diabetes Randomized Clinical Trial (Davies et al., JAMA 2015) (opens in a new tab)PubMed 26284720PubMed
- Efficacy and safety of semaglutide compared with liraglutide and placebo for weight loss: STEP-8 phase 2 trial (O'Neil et al., Lancet 2018) (opens in a new tab)PubMed 30122305PubMed
- Drugs@FDA: liraglutide, Biocon ANDA 217063, rated equivalent to Saxenda (approved February 24, 2026) (opens in a new tab)FDA Label
- Drugs@FDA: liraglutide, Orbicular ANDA 217234, rated equivalent to Saxenda (approved February 24, 2026) (opens in a new tab)FDA Label
- openFDA Drugs@FDA: liraglutide applications and therapeutic equivalence codes (data through October 14, 2026) (opens in a new tab)FDA Label
Related Resources
Related Tools
Storage & Stability
Frequently Asked Questions
How popular is Liraglutide?
Popular. A popularity tier (hot, popular, emerging or niche), based on search volume and community activity.
5,585 papers on PubMed, the US library of medical research. Search them on PubMed (opens in a new tab).
High search interest. A band for how often people search Google for the name each month.
These come from this site's peptide records. They are not live counts.